RESUMEN
OBJECTIVE: To develop software for individualized dosage regimen of valproic acid and carbamazepine according to population pharmacokinetics and Bayesian estimation method. METHODS: Based on the prior population pharmacokinetic (PPK) information, Microsoft Excel 2010 was employed as the input-output interface to run the PPK program, Nonlinear Mixed Effect Modeling (NONMEM), to estimate the PK parameters and design the regimen. RESULTS: The software fulfills the functions of patient information management, initial dosage design, dosage calculation by maximum a posterior Bayesian estimation (MAPB) and compliance assessment. CONCLUSION: The established software provides a powerful tool in the clinical settings to facilitate the individualized therapy for the epilepsy patients.